CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for Nexien Biopharma Inc is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

Nexien Biopharma Inc
4340 E Kentucky Ave Ste 206
Phone: (303) 495-7583p:303 495-7583 GLENDALE, CO  80246-2067  United States Ticker: NXENNXEN
Business Summary
Nexien BioPharma, Inc. is engaged in pre-clinical and drug development activities for certain pharmaceutical formulations that include cannabinoids. The Company is focused on developing and commercializing United States Food and Drug Administration (FDA)-compliant cannabinoid pharmaceuticals, drug delivery systems, and related technologies for diseases, disorders and medical conditions. The Company is utilizing cannabinoids as the active pharmaceutical ingredients to develop synthetic pharmaceuticals in strict accordance with the U.S. FDA pre-clinical and clinical pathways. Its flagship research and development programs are focused on advancing formulations that have the potential to improve the treatment outcomes of certain convulsive disorders and neuromuscular disorders, which includes the treatment of myotonic dystrophy. The Company's wholly owned subsidiaries include Intiva BioPharma Inc., NexN Inc. (NexN) and NexDM Inc.

Scores and Ratings
FRISK®
Score		 Z''
Score		 PAYCE®
Score		 DBT
Index		 Moody's
Rating		 Fitch
Rating		 DBRS
Rating
-Yes-----

Financials, News and Filings
Latest
Statement		 Last
Audit
News		 SEC
Filings		 Bankruptcy
Filings		 Suit &
Judgment
Filings		 Tax
Lien
Filings
9/30/20246/30/2024YesYes---

Industries
SIC Code Description
5621 Women's clothing stores
2834 Pharmaceutical preparations

Officers and Directors

Title
Name
Age		 Title
Date		 Start
Date
President, Chief Executive Officer, Director Arlene H.Stern 48 1/1/1996 7/8/1996
Senior Vice President, Chief Financial Officer and Secretary Thomas J.Villano 47 1/1/1999 3/1/1999
Senior Vice President, Merchandising and Marketing DennisHorstman 53 1/1/1996 12/2/1996
4 additional Officers and Directors records available in full report.

Business Names
Business Name
CRX Bio Holdings LLC
Intiva BioPharma Inc.
Intiva Kotzker Pharmaceuticals Inc.
5 additional Business Names available in full report.

General Information
Outstanding Shares: 70,772,196 (As of 10/22/2024)
Shareholders: 742
Stock Exchange: OTC
Federal Tax Id: 262049376
Fax Number: (302) 645-1280


Copyright © 2024 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Tuesday, December 3, 2024